| CAS NO: | 953778-58-0 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 953778-58-0 |
| 别名 | MK-8998 |
| Canonical SMILES | O=C(N[C@@H](C1=NC=C(OCC(F)(F)F)C=C1)C)CC2=CC=C(C(C)C)C=C2 |
| 分子式 | C20H23F3N2O2 |
| 分子量 | 380.4 |
| 溶解度 | DMSO : ≥ 100 mg/mL (262.88 mM);Water :< 0.1 mg/mL (insoluble) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | MK-8998 is a potent and selective antagonist of the T-type calcium channel. MK-8998 is a potent and selective antagonist of the T-type calcium channel that is being investigated as a potential new therapy for the treatment of schizophrenia. Because MK-8998 does not block D2, 5HT2a, muscarinic, or histaminic receptors, it has the potential for a substantially improved side effect profile compared with currently available atypical antipsychotics[1]. MK-8998 is not effective in treating acutely psychotic inpatients with schizophrenia. There are no significant differences between either MK-8998 or olanzapine versus placebo at any time point. MK-8998 and olanzapine are generally well tolerated but are associated with a higher percentage of adverse events compared with placebo[1]. References: |
m.cnreagent.com